Sarcomatrix

https://lnkd.in/gaCMJanV

Overcoming Investor Objections in Duchenne Drug Development: Why Sarcomatrix Stands Apart Despite enormous unmet need in Duchenne muscular dystrophy (DMD), many investors hesitate to back new programs—citing high clinical risk, crowded pipelines, and capital intensity. At Sarcomatrix, we understand those concerns—and we’ve built a differentiated small molecule approach to address them directly. ✅ Mutation-agnostic, oral, and scalable ✅ Designed for global reimbursement, not gene therapy pricing ✅ Potent preclinical efficacy with functional and histological improvement ✅ Initiating first-in-human trials in 2025 with <$5M We’re not pursuing another dystrophin-restoration strategy. Instead, our lead drug, S-969, activates conserved regeneration pathways across all DMD mutations—and has potential utility in other muscle-wasting conditions like sarcopenia and cachexia. With preclinical, CMC, and regulatory milestones de-risked, we are raising a $5M Seed+ round to complete IND-enabling studies and enter human trials. We’re seeking a syndicate lead who shares our belief: There is a smarter, more scalable path to treating DMD—and Sarcomatrix is on it. 📩 Contact: David Craig, CEO 📧 david@sarcomatrix.com 📑 Investor deck & data room available on request

With funding secured, we are prepared to initiate Phase I trials for our lead oral therapy this quarter. This is a critical step toward delivering a transformative treatment to children in need—one that could significantly improve both the quality and length of their lives. If you're interested in helping us accelerate this mission, I invite you to schedule a meeting with me. To those who have already invested—thank you for your belief in our vision.

90% of Muscular Dystrophy patients still have no treatment. Even within Duchenne—one of the most studied forms—55% of patients remain unaddressed. At Sarcomatrix, we're advancing S-969, a first-in-class oral small molecule designed to preserve and regenerate muscle—addressing the core pathology shared across these devastating diseases. If successful, S-969 could offer hope to the vast majority of patients still waiting for a therapy that helps them rebuild what they’ve lost. #musculardystrophy #duchenne #raredisease #drugdevelopment #biotech #Sarcopenia #DMD #muscleregeneration #S969

Congratulations to Hailey Hermann and the Burkin Lab at UNR! Their work in translational research is advancing our understanding of Laminin-α2-related muscular dystrophy (LAMA2-CMD)—a devastating neuromuscular disorder with no current cure. Using spatial-omics, their research reveals loss of adhesion-signaling and ROS in both human and mouse models of LAMA2-CMD, and importantly, demonstrates that treatment with recombinant human laminin-111 (rhLAM-111) restores these pathways. This study highlights laminin’s critical role in skeletal muscle signaling, growth, and survival, providing compelling evidence for rhLAM-111 as a potential therapeutic strategy. Exciting work that brings hope to LAMA2-CMD patients and underscores the power of innovative research in advancing neuromuscular disease treatments. #TranslationalResearch #LAMA2CMD #MuscularDystrophy #SpatialOmics #UNR #BurkinLab

Exciting news from Sarcomatrix Therapeutics! We will be presenting our latest preclinical data on S969, a novel Alpha7 Integrin-enhancing small molecule for Duchenne Muscular Dystrophy (DMD), at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas next week. Our poster presentation will highlight S969’s potential as an oral, mutation-independent therapy designed to strengthen muscle fibers and improve cardiac health—addressing critical unmet needs in DMD. Join us in the Exhibit Hall, March 16-18, and learn how S969 could change the treatment landscape for DMD. #Sarcomatrix #Duchenne #Biotech #MDA2025 #MuscleHealth

Exciting milestone for Sarcomatrix Therapeutics! We are pleased to announce the renewal of our EU Orphan Drug Designation for recombinant human laminin-111 (rhLAM-111) as a potential therapy for LAMA2-related muscular dystrophy (LAMA2-RD). This renewal underscores our commitment to advancing breakthrough treatments for rare neuromuscular disorders. In addition, we are expanding our research into Duchenne Muscular Dystrophy (DMD), where rhLAM-111 has shown potential in preclinical models to support muscle integrity and function. With no approved treatments available for LAMA2-RD and limited options for DMD, our mission remains clear: to bring life-changing therapies to those who need them most. The EU Orphan Drug Designation provides regulatory support, market exclusivity, and financial incentives, accelerating our path toward clinical trials. We are committed to scientific excellence and innovation in muscle disease therapy. Stay tuned for more updates! #Biotech #OrphanDrugs #NeuromuscularDisorders #LAMA2RD #Duchenne #Sarcomatrix #MuscleHealth 🔗 Read more: Sarcomatrix Press Release

📢 Sarcomatrix Therapeutics to Present at the 2025 BIO CEO & Investor Conference Sarcomatrix Therapeutics is advancing the future of muscle disease treatment. We’re excited to announce our participation at the 2025 BIO CEO & Investor Conference, where David Craig, CEO, will present the latest progress on our lead candidate, S-969—a first-in-class small molecule targeting the Hippo-YAP axis for Duchenne muscular dystrophy (DMD), sarcopenia, and other degenerative muscle disorders. 📍 Event Details: 🗓 Monday, February 10, 2025 | 🕙 10:00 AM ET 📍 Royale Room, New York Marriott Marquis With Phase 1 clinical trials on the horizon in 2025, this is a pivotal moment for Sarcomatrix. Our robust preclinical data, regulatory strategy, and investor momentum position us to make a meaningful impact on patient care. We look forward to connecting with investors, partners, and industry leaders to drive innovation forward. If you're attending, let’s meet! 🔗 For partnership opportunities or to schedule a meeting, contact: David Craig, CEO at david.craig@sarcomatrix.com #BIOCEOInvestor #Biotech #Duchenne #Sarcopenia #MuscleDisease #Sarcomatrix #BiotechInvesting

I had the opportunity to speak to Moe Alsumidaie, Chief Editor At Clinical Trials Vanguard Sarcomatrix Therapeutics and our efforts in tackling muscle wasting diseases. It was a pleasure to share our work on S-969, an oral small molecule that targets the Hippo-YAP pathway. During the interview, we delved into regulatory hurdles, clinical trial strategies, and key partnerships—critical factors in bringing our innovative treatment to patients in need. At Sarcomatrix, we are dedicated to driving S-969 forward through biomarker-based trials and strategic collaborations, with a goal of market entry by 2029! Check out Moe's article for more details: https://lnkd.in/gn4gDpMp? #Sarcomatrix #MuscleWastingDisease #Biotech #ClinicalTrials #Innovation

Honoring Excellence: Dr. Katherine Mathews Receives the 2025 MDA Legacy Award Sarcomatrix extends heartfelt congratulations to Dr. Katherine Mathews, a trailblazer in neuromuscular research, on being honored with the 2025 MDA Legacy Award for Achievement in Clinical Research. Dr. Mathews' groundbreaking work at the University of Iowa has significantly advanced our understanding and treatment of neuromuscular disorders such as Duchenne muscular dystrophy (DMD), limb-girdle muscular dystrophy (LGMD), and Friedreich's ataxia. Her contributions, from early discoveries in facioscapulohumeral muscular dystrophy genetics to her leadership in clinical trials and mentorship at the Iowa Wellstone Muscular Dystrophy Specialized Research Center, are nothing short of transformative. We applaud Dr. Mathews' dedication to scientific excellence and her role in shaping the future of neuromuscular disease research. The 2025 MDA Clinical & Scientific Conference will take place March 16-19 in Dallas, TX, where Dr. Mathews will be celebrated alongside Donavon Decker, recipient of the Community Impact Award. #MuscularDystrophy #ClinicalResearch #NeuromuscularDiseases #Sarcomatrix